Octreotide pamoate (subcutaneous injection, 30 mg/kg, once) can inhibit tumor growth significantly with no effect on body weight[1].
Octreotide pamoate (intramuscular injection, 60 mg/kg, every 21 days, 42 days) inhibits serum insulin-like growth factor (IGF-I) without toxicity in dogs with appendicular osteosarcoma (OSA)[2].
Octreotide pamoate (subcutaneous injection, 40 μg/kg, Every 12 hours, 8 days) improves hepatic glycogen synthesis in obese male Sprague?Dawley (SD) rats[3].
| Animal Model: | Female nude mice (nu/nu Balbc-A weighing 19-22 g)[1] |
| Dosage: | 30 mg/kg |
| Administration: | Subcutaneous injection; once |
| Result: | Showed that the average volume of tumors treated was 25.8% of the control group and no effect on body weight. |
| Animal Model: | Dogs with appendicular OSA[2] |
| Dosage: | 60 mg/kg |
| Administration: | Intramuscular injection; every 21 days; 42 days |
| Result: | Resulted in a 43% decrease in mean serum IGF-I compared with mean baseline concentrations. |
| Animal Model: | Male Sprague?Dawley (SD) rats (3 weeks; 40-60 g)[3] |
| Dosage: | 40 μg/kg |
| Administration: | Subcutaneous injection; every 12 hours; 8 days |
| Result: | Significantly improved fat deposition and reduced lipid infiltration. |
